GOSS News
Archived Headlines
- US IPO Weekly Recap: Gossamer Bio launches 20-day IPO, with more IPOs coming 01/25/19
- Gossamer Bio sets terms for $230 million IPO, bypassing shutdown with rarely-used 20-day rule 01/23/19
- These will be the first IPOs of 2019 01/09/19
- Tis the season for big biotechs: Gossamer Bio files for a $265 million IPO 12/21/18
US IPO Weekly Recap: Two billion-dollar biotechs cap a mixed week for biotech IPOs
In the second week after the SEC opened we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP), along with three SPACs, also priced their IPOS. ...read more
Gossamer Bio prices upsized IPO at $16
Gossamer Bio, which is developing in-licensed immunotherapies for asthma and other indications, raised $276 million by offering an upsized 17.3 million shares at $16, the indicated IPO price. Insiders indicated an interest in purchasing $100 million (36% of...read more
2 billion-dollar biotechs will IPO this week; here's how the last 5 performed
One prediction from our 2018 Annual IPO Review is already coming true: Biotech IPOs are getting bigger. Two biotech IPOs with proposed billion-dollar valuations are slated to price this week. The first, Alector (ALEC), plans to raise $176 million at a...read more
US IPO Week Ahead: 2 billion-dollar biotechs in a 4-IPO week
Four IPOs plan to raise $523 million in the week ahead. Biotechs are still a strong force in the IPO market with three early-stage immunotherapy plays on the docket, including two with proposed billion-dollar valuations. A micro-cap Florida bank rounds out the...read more